(Q57012269)

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Host-bacterial mutualism in the human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Gut microorganisms, mammalian metabolism and personalized health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The gut microbiota as an environmental factor that regulates fat storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The role of analytical sciences in medical systems biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Metabonomics and its role in drug development and disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Metabolomic approaches to phenotype characterization and applications to complex diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The emerging field of lipidomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Automated Identification and Quantification of Glycerophospholipid Molecular Species by Multiple Precursor Ion Scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Elucidation of double bond position in unsaturated lipids by ozone electrospray ionization mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Shifting emphasis from pharmacogenomics to theragnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

A change in the market--investing in diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Metabolomic mapping of atypical antipsychotic effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Intestinal lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Mechanisms involved in chylomicron remnant lipid uptake by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The induction of macrophage foam cell formation by chylomicron remnants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

ABCA1: at the nexus of cholesterol, HDL and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effect of cell cholesterol content on apolipoprotein B secretion and LDL receptor activity in the human hepatoma cell line, HepG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Fatty liver, insulin resistance, and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The proprotein convertases are potential targets in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Mechanisms and consequences of cellular cholesterol exchange and transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The role of high-density lipoproteins in oxidation and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Is raising HDL a futile strategy for atheroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

HDL: the metabolism, function, and therapeutic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Variations and increase in use of statins across Europe: data from administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Cholesterol absorption blockade with ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

On the mechanisms of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Statin safety: lessons from new drug applications for marketed statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Statin-associated peripheral neuropathy: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Clinical perspectives of statin-induced rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Genetic risk factors associated with lipid-lowering drug-induced myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665

High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.6.665